Treatment of childhood kaposiform hemangioendothelioma with sirolimus

Julie Blatt; Joseph Stavas; Billie Moats-Staats; John Woosley; Dean S. Morrell

doi:10.1002/pbc.22766

Treatment of childhood kaposiform hemangioendothelioma with sirolimus

Julie Blatt, Joseph Stavas, Billie Moats-Staats, John Woosley, Dean S. Morrell

Research output: Contribution to journal › Article › peer-review

98 Scopus citations

Abstract

Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.

Original language	English
Pages (from-to)	1396-1398
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	55
Issue number	7
DOIs	https://doi.org/10.1002/pbc.22766
State	Published - Dec 2010
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Pediatrics, Perinatology, and Child Health
Hematology

Access to Document

10.1002/pbc.22766

Fingerprint Dive into the research topics of 'Treatment of childhood kaposiform hemangioendothelioma with sirolimus'. Together they form a unique fingerprint.

Cite this

@article{deebf915be774c228476606973ca35b9,

title = "Treatment of childhood kaposiform hemangioendothelioma with sirolimus",

abstract = "Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.",

author = "Julie Blatt and Joseph Stavas and Billie Moats-Staats and John Woosley and Morrell, {Dean S.}",

year = "2010",

month = dec,

doi = "10.1002/pbc.22766",

language = "English",

volume = "55",

pages = "1396--1398",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "7",

}

TY - JOUR

T1 - Treatment of childhood kaposiform hemangioendothelioma with sirolimus

AU - Blatt, Julie

AU - Stavas, Joseph

AU - Moats-Staats, Billie

AU - Woosley, John

AU - Morrell, Dean S.

PY - 2010/12

Y1 - 2010/12

N2 - Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.

AB - Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.

UR - http://www.scopus.com/inward/record.url?scp=78049294338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049294338&partnerID=8YFLogxK

U2 - 10.1002/pbc.22766

DO - 10.1002/pbc.22766

M3 - Article

C2 - 20730884

AN - SCOPUS:78049294338

VL - 55

SP - 1396

EP - 1398

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -